IL325831A - פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית - Google Patents
פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזיתInfo
- Publication number
- IL325831A IL325831A IL325831A IL32583126A IL325831A IL 325831 A IL325831 A IL 325831A IL 325831 A IL325831 A IL 325831A IL 32583126 A IL32583126 A IL 32583126A IL 325831 A IL325831 A IL 325831A
- Authority
- IL
- Israel
- Prior art keywords
- formulations
- cns disorders
- rock2 inhibitors
- rock2
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363514042P | 2023-07-17 | 2023-07-17 | |
| PCT/IB2024/056936 WO2025017500A1 (en) | 2023-07-17 | 2024-07-17 | Formulations of rock2 inhibitors for cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325831A true IL325831A (he) | 2026-03-01 |
Family
ID=92302638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325831A IL325831A (he) | 2023-07-17 | 2024-07-17 | פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2024294840A1 (he) |
| IL (1) | IL325831A (he) |
| WO (1) | WO2025017500A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026053168A1 (en) * | 2024-09-06 | 2026-03-12 | Graviton Bioscience Bv | Amorphous forms of a rock2 inhibitor and formulations thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4201178C2 (de) | 1992-01-17 | 1995-12-07 | Alfatec Pharma Gmbh | Verfahren zur Herstellung von Weichgelatinekapseln nach einem Tropfverfahren |
| NL1009107C2 (nl) | 1997-11-12 | 1999-06-15 | Banner Pharmacaps Inc | Gelatine-uitspreidende doos met meervoudige, aanpasbare poortklep en meerlagig zacht gel. |
| JP2002529398A (ja) | 1998-11-11 | 2002-09-10 | バイオプログレス・テクノロジー・インターナショナル・インコーポレイテッド | 薬剤配達系のためのカプセル |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| US10857157B2 (en) * | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| WO2019000682A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| CN110582489B (zh) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| EA202090306A1 (ru) * | 2017-07-21 | 2020-06-25 | Кадмон Корпорейшн, Ллк | ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ |
| CN112969694B (zh) | 2018-11-09 | 2023-06-13 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途 |
| BR112021017354A2 (pt) | 2019-03-01 | 2021-11-16 | Beijing Tide Pharmaceutical Co Ltd | Método para o tratamento de doença hepática adiposa e/ou esteatoepatite |
| CA3144113A1 (en) | 2019-06-25 | 2020-12-30 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating idiopathic pulmonary fibrosis |
| KR20230058466A (ko) | 2020-08-31 | 2023-05-03 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | 신규한 rho-연관 단백질 인산화효소 억제제의 제조 방법 및 제조 방법 중의 중간체 |
| JP2023539276A (ja) * | 2020-08-31 | 2023-09-13 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Rho関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用 |
| KR20240095429A (ko) * | 2021-11-16 | 2024-06-25 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Rock2 억제제의 나노결정 제제 및 이의 제조방법 |
-
2024
- 2024-07-17 IL IL325831A patent/IL325831A/he unknown
- 2024-07-17 AU AU2024294840A patent/AU2024294840A1/en active Pending
- 2024-07-17 WO PCT/IB2024/056936 patent/WO2025017500A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024294840A1 (en) | 2026-02-26 |
| WO2025017500A1 (en) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295364B1 (he) | נגזרות פסילוצין כחומר פסיכודלי סרוטונרגי לטיפול בהפרעות של מערכת העצבים המרכזית | |
| IL316616A (he) | מעכבי rock2 | |
| IL315722A (he) | תרכובות אינדאזול מותמרות עם פיפראזין כמעכבי parg | |
| EP4100403A4 (en) | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISEASES | |
| IL325831A (he) | פורמולציות של מעכבי rock2 עבור הפרעות במערכת העצבים המרכזית | |
| ZA202212146B (en) | Inhibitors of nek7 kinase | |
| EP4452967A4 (en) | Inhibitors of sars-cov-2 | |
| IL325528A (he) | שימוש בגליצרידים בפורמולציות lnp | |
| IL325596A (he) | תכשירי רוקחות למעכבים של nek7 קינאז | |
| CA3298108A1 (en) | Formulations of rock2 inhibitors for cns disorders | |
| IL325832A (he) | פורמולציות ושימושים של מעכבי rock2 ל- als | |
| IL309182A (he) | מעכבי פרוטיאז לטיפול בזיהומי נגיף הקורונה | |
| EP4153616A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| EP4100065A4 (en) | USE OF MIRNA-485 INHIBITORS TO TREAT TAUOPATHY | |
| IL319571A (he) | R-טריהקסיפנידיל לטיפול בהפרעות תנועה | |
| GB202201708D0 (en) | Compositions for oral delivery of biotherapeutics | |
| CA3273444A1 (en) | Inhibitors of rock2 | |
| HK40122640A (en) | Inhibitors of rock2 | |
| HK40076349A (en) | Allogeneic composition for treatment of cns disorders | |
| IL320731A (he) | הרכבים ושיטות למחלות מערכת העצבים המרכזית | |
| HK40082232A (en) | Compounds and compositions for treating cns disorders | |
| HK40082254A (en) | Compounds and compositions for treating cns disorders | |
| IL317760A (he) | תולדות בנזוקרבאזול כמעכבי drp1 | |
| CA3297265A1 (en) | Pharmaceutical compositions for inhibitors of nek7 kinase | |
| GB202203181D0 (en) | Inhibitors of elF4A |